Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. This trial compared IDegAsp with biphasic insulin aspart 30 (BIAsp 30) in adults with type 2 diabetes inadequately controlled with once- or twice-daily (OD or BID) pre- or self-mixed insulin with or without oral antidiabetic drugs.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Care

Title: Diabetes care

ISSN (Electronic): 1935-5548

ISSN (Print): 0149-5992

Publication date (Electronic): Aug 2014

Volume: 37

Issue: 8

Affiliations

[1 ] University of Sydney, Royal North Shore Hospital, Australia greg.fulcher@sydney.edu.au.

[2 ] Aarhus University Hospital, Aarhus, Denmark.

[3 ] St. Johns Medical College Hospital, Bangalore, India.

[4 ] Bydgoszcz Diabetes and Endocrinology Center, Bydgoszcz, Poland.

[5 ] Novo Nordisk A/S, Søborg, Denmark.

[6 ] School of Medicine, University of Eastern Finland, Helsingfors, Finland.

Article

Publisher Item ID: dc13-2908

DOI: 10.2337/dc13-2908

PubMed ID: 24812432

SO-VID: 8f3edca1-e01f-420c-9dd0-6601632f7b9a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 48

See all cited by